Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: A EUROCORD, EBMT, EWOG-MDS,CIBMTR study

Franco Locatelli, Alessandro Crotta, Annalisa Ruggeri, Mary Eapen, John E. Wagner, Margaret L. MacMillan, Marco Zecca, Joanne Kurtzberg, Carmem Bonfim, Ajay Vora, Cristina Díaz De Heredia, Lochie Teague, Jerry Stein, Tracey A. O'Brien, Henrique Bittencourt, Adrienne Madureira, Brigitte Strahm, Christina Peters, Charlotte Niemeyer, Eliane GluckmanVanderson Rocha

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

We retrospectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unrelated donor umbilical cord blood transplantation. Median age at diagnosis and at transplantation was 1.4 years (age range, 0.1-6.4 years) and 2.2 years (age range, 0.5-7.4 years), respectively. Before transplantation, 88 patients received chemotherapy; splenectomy was performed in 24 patients. Monosomy of chromosome 7 was the most frequent cytogenetic abnormality, found in 24% of patients. All but 8 patients received myeloablative conditioning; cyclosporine plus steroids was the most common graft-versus-host disease prophylaxis. Sixteen percent of units were HLA-matched with the recipient, whereas 43%and 35% had either 1 or 2 to 3 HLA disparities, respectively. The median number of nucleated cells infused was 7.1 × 107/kg (range, 1.7-27.6 × 107/kg). With a median follow-up of 64 months (range, 14-174 months), the 5-year cumulative incidences of transplantation-related mortality and relapse were 22% and 33%, respectively. The 5-year disease-free survival rate was 44%. In multivariate analysis, factors predicting better disease-free survival were age younger than 1.4 years at diagnosis (hazard ratio [HR], 0.42; P = .005), 0 to 1 HLA disparities in the donor/recipient pair (HR, 0.4; P = .009), and karyotype other than monosomy 7 (HR, 0.5; P = .02). Umbilical cord blood transplantation may cure a relevant proportion of children with juvenile myelomonocytic leukemia. Because disease recurrence remains the major cause of treatment failure, strategies to reduce incidence of relapse are warranted.

Original languageEnglish (US)
Pages (from-to)2135-2141
Number of pages7
JournalBlood
Volume122
Issue number12
DOIs
StatePublished - Sep 19 2013

Fingerprint Dive into the research topics of 'Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: A EUROCORD, EBMT, EWOG-MDS,CIBMTR study'. Together they form a unique fingerprint.

Cite this